secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2022-02-01T23:59:59+00:00
Accession:  0001104659-22-010000
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals appoints Erin Parsons to board; Stephen From resigns as Executive Chairman
--------------------------------------------------------------------------------

- Stephen From voluntarily resigned as Executive Chairman and board member effective Jan 31, 2022; no disagreement cited.
- From receives 18 monthly severance payments of $33,333, a lump sum of $300,000, COBRA subsidies, and accelerated vesting.
- Erin Parsons appointed as independent Class III director; she founded Parsons Medical Communications and has ophthalmic expertise.
- Paul Chaney appointed as non-executive Chairman, previously serving as Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/0001104659-22-010000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/tm225039d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-010000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer